Perimeter Medical Imaging AI (PINK) AI Stock Analysis

• Market Cap: C$26.73M
• Dividend Yield: N/A
• Average Volume (3M): 53.64K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.48
• Revenue Growth: 219.12%
• EPS Growth: -15.92%
• Country: CA
• Employees: 65
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Devices
• EPS (TTM): -0.06
• Shares Outstanding: 118,779,976
• 10 Day Avg. Volume: 54,759
• 30 Day Avg. Volume: 53,641
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: C$0.50
• Price Target Upside: 108.33% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 1

• Rating: 48 Neutral
• Price Target: C$0.00 ▼(-100.00% Downside)

Perimeter Medical Imaging AI's stock score is primarily impacted by financial performance challenges, including profitability and cash flow issues. The earnings call provided positive insights into revenue growth and product utilization, but these are offset by increased net loss and cash constraints. Technical analysis shows mixed signals, with short-term momentum but longer-term bearish trends. Valuation remains unattractive due to negative earnings.

Perimeter Medical Imaging AI Business Overview & Revenue Model

Company Description

Perimeter Medical Imaging AI, Inc., a medical technology company, develops and commercializes advanced imaging tools that allow surgeons, radiologists, and pathologists to visualize microscopic tissue structures during a clinical procedure. The company offers an optical coherence tomography (OCT) imaging system provides clinicians with cross-sectional of tissues down to 2 mm dept. This OCT imaging system consists of S-series OCT, B-series OCT, and OCT imaging console. It also offers ImgAssist, an artificial intelligence technology that enhances the efficiency of image review and be an additional powerful tool when combined with Perimeter OCT to aid physicians with real-time margin visualization and assessment to improve surgical outcomes for patients and reducing the likelihood of needing additional surgeries. In addition, the company offers proprietary image library and consumable specimen containers to hospitals and cancer surgery centers. Perimeter Medical Imaging AI, Inc. was founded in 2013 and is headquartered in Toronto, Canada.

How the Company Makes Money

Perimeter Medical Imaging AI generates revenue primarily through the sale and distribution of its proprietary imaging systems to hospitals and surgical centers. The company's revenue model includes direct sales of its devices, as well as recurring revenue from service and maintenance contracts, and potentially from software licenses for its AI-driven platform. Key revenue streams also include partnerships with healthcare institutions and collaborations with research organizations that leverage its technology for clinical studies and advancements in surgical oncology. Additionally, strategic alliances and collaborations with other medical technology firms can contribute to its earnings by expanding the reach and application of its imaging solutions.

Perimeter Medical Imaging AI Financial Statement Overview

Summary

Perimeter Medical Imaging AI exhibits strong revenue growth but continues to face significant profitability challenges with a high net loss and negative cash flow. The balance sheet shows low leverage, which is good for stability, but declining equity and assets are concerns. Overall, the company is in a growth phase but needs to improve operational efficiencies to achieve sustainable financial health.

Income Statement

Perimeter Medical Imaging AI has shown significant revenue growth with a TTM revenue of $1,298,133 compared to $846,194 in the previous year. However, the company continues to operate at a net loss, with a TTM net income of -$15,589,354, indicating ongoing challenges in achieving profitability. The gross profit margin is healthy at 60.6%, but the net profit margin remains negative due to high operating expenses.

Balance Sheet

The company's balance sheet reflects a moderate financial position with a debt-to-equity ratio of 0.02, indicating low leverage. However, stockholders' equity has decreased over the past year, and the equity ratio stands at 75.9%. The reduction in total assets and equity might pose potential risks if the trend continues without a corresponding increase in profitability.

Cash Flow

Cash flow analysis shows challenges with a negative free cash flow of -$17,114,155 for TTM, indicating cash burn issues. The operating cash flow to net income ratio is slightly negative, which suggests difficulties in converting operational activities into cash. Despite negative cash flows, the company has managed to secure financing.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	1.56M	846.19K	403.53K	132.77K	11.34K	0.00
Gross Profit	968.18K	535.11K	206.42K	100.63K	5.04K	-47.57K
EBITDA	-15.46M	-12.64M	-17.92M	-11.72M	-15.95M	-6.11M
Net Income	-16.29M	-13.39M	-18.94M	-3.59M	-16.76M	-8.00M
Balance Sheet
Total Assets	6.92M	14.33M	27.09M	34.60M	9.98M	13.16M
Cash, Cash Equivalents and Short-Term Investments	1.37M	6.18M	18.43M	28.44M	5.14M	11.70M
Total Debt	117.05K	137.48K	192.89K	325.68K	441.17K	400.81K
Total Liabilities	2.41M	3.87M	7.10M	8.49M	2.56M	2.40M
Stockholders Equity	4.51M	10.45M	15.06M	26.11M	7.42M	10.76M
Cash Flow
Free Cash Flow	-15.78M	-16.90M	-15.17M	-13.86M	-16.03M	-8.26M
Operating Cash Flow	-13.86M	-14.72M	-14.70M	-11.87M	-13.91M	-8.26M
Investing Cash Flow	-1.80M	-1.90M	206.01K	-1.75M	-1.45M	7.24M
Financing Cash Flow	10.44M	8.58M	234.47K	40.28M	10.06M	9.84M

Perimeter Medical Imaging AI Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.24
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:PINK, the sentiment is Negative. The current price of 0.24 is above the 20-day moving average (MA) of 0.23, above the 50-day MA of 0.24, and below the 200-day MA of 0.38, indicating a bearish trend. The MACD of <0.01 indicates Negative momentum. The RSI at 44.32 is Neutral, neither overbought nor oversold. The STOCH value of 36.19 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:PINK.

Perimeter Medical Imaging AI Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
QIPT	66 Neutral	162.05M	-11.16	-6.31%	―	-0.70%	-102.48%
PRN	54 Neutral	224.80M	-3.56	―	―	64.42%	-21.09%
PINK	48 Neutral	C$26.73M	―	-233.44%	―	219.12%	-15.92%
ASG	48 Neutral	22.64M	-14.15	-28.62%	―	17.61%	-19.19%
VPT	44 Neutral	17.61M	-3.72	―	―	88.47%	11.88%
TLT	40 Underperform	48.84M	-10.86	-205.86%	―	16.00%	9.79%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

Perimeter Medical Imaging AI Corporate Events

Perimeter Medical Imaging AI Joins ASBrS Industry Relations Council

Perimeter Medical Imaging AI has joined the American Society of Breast Surgeons’ Industry Relations Council, a move that aligns with its strategic goals to enhance its presence in the breast surgery field. This membership is expected to facilitate collaboration with key industry leaders and support the company’s efforts to gain commercial traction for its current and next-generation imaging systems, potentially impacting its market positioning and stakeholder engagement.

The most recent analyst rating on (TSE:PINK) stock is a Hold with a C$0.50 price target. To see the full list of analyst forecasts on Perimeter Medical Imaging AI stock, see the TSE:PINK Stock Forecast page.

Perimeter Medical Imaging AI Appoints Dr. Ted James as Chief Medical Officer to Drive Growth

Perimeter Medical Imaging AI has appointed Dr. Ted James as Chief Medical Officer to bolster its medical strategy and accelerate the adoption of its technology. Dr. James, with extensive experience in surgical oncology and healthcare innovation, will support the company’s growth as it moves towards commercialization of its next-generation AI-enabled imaging tools. His appointment is expected to enhance the company’s industry positioning by demonstrating the medical and practical value of its Perimeter B-Series technology, which is advancing toward FDA approval.

The most recent analyst rating on (TSE:PINK) stock is a Hold with a C$0.50 price target. To see the full list of analyst forecasts on Perimeter Medical Imaging AI stock, see the TSE:PINK Stock Forecast page.

Perimeter Medical Imaging AI Reports Strong Q2 2025 Results and Advances in Imaging Technology

Perimeter Medical Imaging AI reported a significant increase in revenue for the second quarter of 2025, driven by the growing adoption of its FDA-cleared Perimeter S-Series device. The company also highlighted the promising development of its next-generation Perimeter B-Series device, which integrates AI technology to improve surgical decision-making. Recent partnerships and the launch of a new registry aim to support further advancements in their imaging technology. The company’s financial health was bolstered by a successful prospectus offering, raising approximately $3.8 million to support ongoing operations and development efforts.

The most recent analyst rating on (TSE:PINK) stock is a Hold with a C$0.50 price target. To see the full list of analyst forecasts on Perimeter Medical Imaging AI stock, see the TSE:PINK Stock Forecast page.

Perimeter Medical Imaging AI Reports Strong Q2 Growth and Strategic Leadership Changes

Perimeter Medical Imaging AI, Inc. announced preliminary unaudited revenues for the second quarter of 2025, showing significant growth with a 100% year-over-year increase and a 50% rise in recurring revenue compared to the previous quarter. The company is implementing a 30% reduction in operating costs and has made strategic leadership changes to support its growth, including the appointment of new vice presidents and the creation of an Industry Advisory Board to guide its commercial strategy.

The most recent analyst rating on (TSE:PINK) stock is a Buy with a C$3.00 price target. To see the full list of analyst forecasts on Perimeter Medical Imaging AI stock, see the TSE:PINK Stock Forecast page.

Perimeter Medical Imaging AI Raises $5.35 Million in Prospectus Offering

Perimeter Medical Imaging AI, Inc. has successfully closed the final tranche of its prospectus offering, raising a total of approximately $5.35 million. The funds will be used to advance the commercialization of their technology, establish clinical evidence, and continue product development, which could strengthen their market position and benefit stakeholders by enhancing their innovative imaging solutions for cancer surgery.

The most recent analyst rating on (TSE:PINK) stock is a Buy with a C$3.00 price target. To see the full list of analyst forecasts on Perimeter Medical Imaging AI stock, see the TSE:PINK Stock Forecast page.

Medical City Dallas Adopts Perimeter’s Advanced Imaging Technology

Medical City Dallas Hospital has adopted Perimeter Medical Imaging AI’s S-Series OCT technology for high-resolution tissue visualization during surgeries. This adoption follows the hospital’s participation in a pivotal trial of Perimeter’s B-Series device, which integrates AI and is under FDA evaluation for breast-conserving surgeries. The S-Series OCT, cleared by the FDA in 2021, offers cellular-level imaging, making it ideal for surgical margin visualization. This deployment marks a significant step in Perimeter’s nationwide technology rollout, potentially enhancing surgical outcomes and positioning the company as a leader in advanced medical imaging solutions.

The most recent analyst rating on (TSE:PINK) stock is a Buy with a C$3.00 price target. To see the full list of analyst forecasts on Perimeter Medical Imaging AI stock, see the TSE:PINK Stock Forecast page.